Protoporphyria, erythropoietic, 1
MONDO:0008319An erythropoietic protoporphyria caused by biallelic variants in FECH (an autosomal recessive inheritance pattern) and causing primarily accumulation of protoporphyrin IX. Symptoms include extremely painful photosensitivity in childhood, possible microcytic anemia, cholelithiasis, and ~5% of patients develop liver failure. The majority of individuals with FECH-related erythropoietic protoporphyria harbor a hypomorphic variant (NM_000140.5:c.315-48T>C), which reduces enzyme levels by ~35%, in trans to a second pathogenic variant. Clinically individuals with this form of porphyria cannot be distinguished from those with ALAS2-related erythropoietic protoporphyria.
Also known as: erythropoietic protoporphyria, protoporphyria, erythropoietic, EPP1, FECH-related erythropoietic protoporphyria, ferrochelatase deficiency, heme synthetase deficiency, protoporphyria, erythropoietic, 1, EPP
171 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Blood RNA may reveal hidden liver cancers
Diagnosis TerminatedThis study looked at whether tiny bits of RNA in the blood can serve as markers for liver disease and liver cancer. Researchers collected blood samples from nearly 1,900 people with liver cancer, cirrhosis, or chronic liver disease. The goal was to see if these RNA markers could …
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Ear device aims to cut opioid use after liver transplant
Symptom relief TerminatedThis study tested a small device worn on the ear that uses mild electrical pulses to help control pain after a liver transplant. The goal was to see if it could reduce the need for strong painkillers like opioids. The study was stopped early and included 27 adults waiting for a l…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Liver study of cancer drug amcenestrant halted early
Knowledge-focused TerminatedThis early-stage study looked at how the drug amcenestrant is processed in the body of women aged 40-75 with mild or moderate liver problems, compared to women with healthy livers. The goal was to understand dosing and safety. However, the trial was terminated before completion, …
Phase: PHASE1 • Sponsor: Sanofi • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC